Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03921294 · ClinicalTrials.gov registry record · Phase 4
HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor
A Phase 4 study, sponsored by Indiana Hemophilia &Thrombosis Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT03921294 is a Phase 4 study that was terminated before completion, run by Indiana Hemophilia &Thrombosis Center. The registered enrollment target is 1 participants.
The verdict
NCT03921294, a Phase 4 study, was terminated before completion, sponsored by Indiana Hemophilia &Thrombosis Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a single arm, phase 4, prospective, open-label, United States single-center study to assess the hemostatic efficacy and safety of Hemlibra (emicizumab) for hemostatic control of hemophilia A patients (baseline FVIII level \<40%) with and without inhibitors with hemophilic pseudotumors; secondary outcomes will assess changes in quality of life and activity level in treated patients.
Interventions
- DRUG Emicizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2022-03-16 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03921294
The ClinicalTrials.gov registry entry for NCT03921294 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana Hemophilia &Thrombosis Center, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Emicizumab is the first listed.
NCT03921294 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03921294 about?
NCT03921294 is a clinical study titled "HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor". This is a single arm, phase 4, prospective, open-label, United States single-center study to assess the hemostatic efficacy and safety of Hemlibra (emicizumab) for hemostatic control of hemophilia A patients (baseline FVIII level \<40%) with and without inhibitors with hemophilic pseudotumors; secon...
What is the current status of trial NCT03921294?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2019-05-15. Estimated completion is 2022-03-16.
What interventions are being tested in trial NCT03921294?
The interventions under investigation include: Emicizumab (DRUG).
Who is sponsoring clinical trial NCT03921294?
This trial is sponsored by Indiana Hemophilia &Thrombosis Center, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.